A Phase 2 interventional study of Sulforaphane Nutraceutical and Identical-appearing Placebo in Schizophrenia and Schizoaffective Disorder, sponsored by Sheppard Pratt Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-27.
Sponsored by Sheppard Pratt Health System · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 670th largest by enrollment of the 1,320 interventional ones that give a count, is one of 49 that started in 2017, is one of 217 in phase 2, and was the 962nd registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,466 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 49 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,320 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,466 have an industry lead sponsor. The 10 most frequent:
Sheppard Pratt Health System is the lead sponsor of 14 studies on the registry; 1 is open to participants now.
Sheppard Pratt Health System has 5 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,466 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
Drug: Sulforaphane Nutraceutical
The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
Drug: Identical-appearing Placebo
Sulforaphane Nutraceutical 6 tablets by mouth daily
Also known as: Avmacol®
Identical-appearing Placebo 6 tablets by mouth daily
Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.
Time frame: 16 weeks (week 2 to week 18)
Change in MATRICS Consensus Cognitive Battery (MCCB) Overall Composite Scores From the Start to the End of the Study
The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.
Time frame: 18 weeks (week 0 to week 18)
Change in C-Reactive Protein From the Start to the End of the Study
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Change in Pentraxin-3 From the Start to the End of the Study
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Change in Anti-Saccharomyces Cerevisiae IgA Class Antibodies From the Start to the End of the Study
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Change in Interleukin-6 From the Start to the End of the Study
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Change in Tumor Necrosis Factor - Alpha From the Start to the End of the Study
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Change in Interferon Gamma From the Start to the End of the Study
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
We enrolled n=64 participants drawn from rehabilitation and treatment programs in Central Maryland. Dates of recruitment: February 2017 - June 2019.
| Milestone | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| Started | 32 | 32 |
| Completed | 32 | 32 |
| Not completed | 0 | 0 |
| Milestone | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| Started | 32 | 32 |
| Completed | 29 | 29 |
| Not completed | 3 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Relocation | 1 | 0 |
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.
| score on a scale | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| Wk 2 (Begin Treatment) PANSS Total Score | 81.0 ± 12.2 | 81.5 ± 13.0 |
| Wk 18 (End Treatment) PANSS Total Score | 81.7 ± 13.3 | 79.7 ± 14.6 |
The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.
| t scores | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| Wk 0 (Baseline) MCCB Score | 25.0 ± 12.0 | 19.5 ± 13.4 |
| Wk 18 (End Treatment) MCCB Score | 26.8 ± 12.6 | 22.8 ± 13.6 |
| ng/ml | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| CRP (Wk 0, Baseline) | 10402.8 ± 13488.2 | 8969.7 ± 9021.6 |
| CRP (Wk 18, End Treatment) | 10198.5 ± 12110.9 | 10224.5 ± 13654.0 |
| ng/ml | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| Pentraxin(Wk 0, Baseline) | 0.414 ± 0.534 | 0.461 ± 0.603 |
| Pentraxin (Wk 18, End Treatment) | 0.394 ± 0.569 | 0.558 ± 0.695 |
| units/ml | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| ASCA IGA (Wk 0, Baseline) | 0.195 ± 0.222 | 0.168 ± 0.163 |
| ASCA IGA (Wk 18, End Treatment) | 0.226 ± 0.277 | 0.176 ± 0.184 |
| pg/m | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| IL-6 (Wk 0, Baseline) | 0.623 ± 0.247 | 0.704 ± 0.478 |
| IL-6 (Wk 18, End Treatment) | 0.694 ± 0.288 | 0.673 ± 0.357 |
| pg/m | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| TNF-a (Wk 0, Baseline) | 0.668 ± 0.393 | 0.538 ± 0.211 |
| TNF-a (Wk 18, End Treatment) | 0.638 ± 0.362 | 0.520 ± 0.263 |
| pg/m | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| IFN-g (Wk 0, Baseline) | 0.514 ± 0.432 | 0.456 ± 0.172 |
| IFN-g (Wk 18, End Treatment) | 0.478 ± 0.335 | 0.526 ± 0.222 |
Collected over Adverse events were collected over an 18 week period, including the 2 week placebo run-in and the 16 week double-blind treatment phase.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sulforaphane Nutraceutical | 0/32 (0%) | 2/32 (6.3%) | 28/32 (87.5%) |
| Identical-appearing Placebo | 0/32 (0%) | 5/32 (15.6%) | 20/32 (62.5%) |
| Event | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| Schizophrenia exacerbationPsychiatric disorders | 2/32 | 2/32 |
| CholecystitisGastrointestinal disorders | 0/32 | 1/32 |
| Knee replacementMusculoskeletal and connective tissue disorders | 0/32 | 1/32 |
| Congestive heart failureCardiac disorders | 0/32 | 1/32 |
| Event | Sulforaphane Nutraceutical | Identical-appearing Placebo |
|---|---|---|
| Respiratory symptomsRespiratory, thoracic and mediastinal disorders | 12/32 | 9/32 |
| Gastrointestinal symptomsGastrointestinal disorders | 12/32 | 6/32 |
| Psychiatric symptomsPsychiatric disorders | 11/32 | 5/32 |
| Endocrine/metabolic symptomsEndocrine disorders | 4/32 | 7/32 |
| OtherGeneral disorders | 4/32 | 5/32 |
| Dermatological symptomsSkin and subcutaneous tissue disorders | 4/32 | 0/32 |
| Cardiovascular symptomsCardiac disorders | 1/32 | 3/32 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/32 | 3/32 |
| Urinary symptomsRenal and urinary disorders | 2/32 | 3/32 |
| Hematological symptomsBlood and lymphatic system disorders | 1/32 | 0/32 |
| Age, Categorical(Participants) | Sulforaphane Nutraceutical | Identical-appearing Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 32 | 32 | 64 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Sulforaphane Nutraceutical | Identical-appearing Placebo | Total |
|---|---|---|---|
| Mean | 42.7 ± 12.3 | 45.8 ± 11.7 | 44.2 ± 12.0 |
| Sex: Female, Male(Participants) | Sulforaphane Nutraceutical | Identical-appearing Placebo | Total |
|---|---|---|---|
| Female | 8 | 7 | 15 |
| Male | 24 | 25 | 49 |
| Race/Ethnicity, Customized(participants) | Sulforaphane Nutraceutical | Identical-appearing Placebo | Total |
|---|---|---|---|
| Caucasian | 18 | 16 | 34 |
| African American | 14 | 16 | 30 |
| Region of Enrollment(participants) | Sulforaphane Nutraceutical | Identical-appearing Placebo | Total |
|---|---|---|---|
| United States | 32 | 32 | 64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Demographic, symptom, and cognitive data will be shared with the National Database for Clinical Trials Related to Mental Illness (NDCT). Access may be obtained through an approved application with the NDCT.
Ran from Feb 2017 to primary completion in Nov 2019, 32 months.
Results were first posted in Jul 2021, 1 year 8 months after primary completion.
Of 44 non-industry phase 2 interventional studies under Schizophrenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's 32 months is below that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Broccoli Sprout/Broccoli Seed Extract Supplement
Sheppard Pratt Health System